Conventional thiopurine therapy with azathioprine or 6-mercaptopurine is an important maintenance strategy in IBD. Unfortunately, many patients have to discontinue this therapy owing to adverse events or lack of efficacy. Given the limited options for alternative maintenance therapies in IBD, as well as our increasing knowledge of thiopurine metabolism, optimizing thiopurine therapy has become an important area of investigation - with the aim of avoiding the need for discontinuation of therapy. In this review, we will discuss recent advances in our understanding of thiopurine metabolism, pharmacogenomics, therapeutic drug monitoring, safety issues, and drug interaction.
|Number of pages||8|
|Journal||Inflammatory Bowel Disease Monitor|
|Publication status||Published - 1 Dec 2012|